» Articles » PMID: 36678377

Many Ways to Communicate-Crosstalk Between the HBV-Infected Cell and Its Environment

Overview
Journal Pathogens
Date 2023 Jan 21
PMID 36678377
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic infection with the hepatitis B virus (HBV) affects an estimated 257 million people worldwide and can lead to liver diseases such as cirrhosis and liver cancer. Viral replication is generally considered not to be cytopathic, and although some HBV proteins may have direct carcinogenic effects, the majority of HBV infection-related disease is related to chronic inflammation resulting from disrupted antiviral responses and aberrant innate immune reactions. Like all cells, healthy and HBV-infected cells communicate with each other, as well as with other cell types, such as innate and adaptive immune cells. They do so by both interacting directly and by secreting factors into their environment. Such factors may be small molecules, such as metabolites, single viral proteins or host proteins, but can also be more complex, such as virions, protein complexes, and extracellular vesicles. The latter are small, membrane-enclosed vesicles that are exchanged between cells, and have recently gained a lot of attention for their potential to mediate complex communication and their potential for therapeutic repurposing. Here, we review how HBV infection affects the communication between HBV-infected cells and cells in their environment. We discuss the impact of these interactions on viral persistence in chronic infection, as well as their relation to HBV infection-related pathology.

Citing Articles

Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study.

Yu J, Bai Y, Cui Z, Cheng C, Ladekarl M, Cheng K J Gastrointest Oncol. 2024; 15(3):1072-1081.

PMID: 38989425 PMC: 11231837. DOI: 10.21037/jgo-24-315.


Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma.

Cai X, Peng S, Xiao X, Huang Z, Zhang P Sci Rep. 2024; 14(1):10996.

PMID: 38744926 PMC: 11094140. DOI: 10.1038/s41598-024-61820-x.


Current and novel modalities for management of chronic hepatitis B infection.

Ibrahim Salama I, Sami S, Salama S, Abdel-Latif G, Shaaban F, Fouad W World J Hepatol. 2023; 15(5):585-608.

PMID: 37305370 PMC: 10251278. DOI: 10.4254/wjh.v15.i5.585.

References
1.
Jung S, Altstetter S, Protzer U . Innate immune recognition and modulation in hepatitis D virus infection. World J Gastroenterol. 2020; 26(21):2781-2791. PMC: 7284172. DOI: 10.3748/wjg.v26.i21.2781. View

2.
Jung S, Jacobs K, Shein M, Schutz A, Mohr F, Stadler H . Efficient and reproducible depletion of hepatitis B virus from plasma derived extracellular vesicles. J Extracell Vesicles. 2020; 10(2):e12040. PMC: 7754750. DOI: 10.1002/jev2.12040. View

3.
Chan K, Au K, Fung W, Wong C, Chan A, Lo R . Sex-specific analysis of microRNA profiles in HBV-associated cirrhosis by small RNA-sequencing. Hepatol Commun. 2022; 6(12):3473-3486. PMC: 9701490. DOI: 10.1002/hep4.2096. View

4.
Wang J, Zhou X, Li X, Guo W, Zhu Q, Zhu B . Fecal Microbiota Transplantation Alters the Outcome of Hepatitis B Virus Infection in Mice. Front Cell Infect Microbiol. 2022; 12:844132. PMC: 9114794. DOI: 10.3389/fcimb.2022.844132. View

5.
Brown R, Goulder P, Matthews P . Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res. 2022; 7:32. PMC: 9520633. DOI: 10.12688/wellcomeopenres.17601.2. View